Palvella Therapeutics (PVLA) reported second-quarter 2026 financial results and provided updates on its QTORIN development programs, including its rolling NDA submission for QTORIN™ rapamycin for microcystic lymphatic malformations.
The company reported cash, cash equivalents and short-term investments of $250.6 million as of June 30, 2026, and a net loss of $21.9 million for the quarter.
- Net loss was $21.9 million, or $1.52 per basic and diluted share, for the three months ended June 30, 2026.
- Research and development expenses were $12.5 million, compared with $5.1 million in the prior-year quarter.
- General and administrative expenses were $8.9 million, compared with $4.1 million in the prior-year quarter.
- Palvella submitted the first module of its rolling NDA to the FDA for QTORIN™ rapamycin in microcystic lymphatic malformations.
- The company said completion of the NDA submission remains on track for the second half of 2026.
- Palvella plans to initiate a Phase 3 trial of QTORIN™ rapamycin for cutaneous venous malformations in the fourth quarter of 2026.
- The company expects to initiate a Phase 2 trial of QTORIN™ pitavastatin for disseminated superficial actinic porokeratosis in the second half of 2026.
$PVLA Insider Trading Activity
$PVLA insiders have traded $PVLA stock on the open market 20 times in the past 6 months. Of those trades, 3 have been purchases and 17 have been sales.
Here’s a breakdown of recent trading of $PVLA stock by insiders over the last 6 months:
- KATHLEEN GOIN (Chief Operating Officer) has made 0 purchases and 17 sales selling 21,510 shares for an estimated $2,515,138.
- GEORGE M JENKINS has made 2 purchases buying 4,445 shares for an estimated $549,973 and 0 sales.
- ELAINE J HERON purchased 2,400 shares for an estimated $300,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$PVLA Hedge Fund Activity
We have seen 125 institutional investors add shares of $PVLA stock to their portfolio, and 44 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PRICE T ROWE ASSOCIATES INC /MD/ added 398,474 shares (+9742.6%) to their portfolio in Q1 2026, for an estimated $49,669,784
- SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC removed 389,420 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $48,541,203
- FRONTIER CAPITAL MANAGEMENT CO LLC added 374,035 shares (+inf%) to their portfolio in Q1 2026, for an estimated $46,623,462
- JENNISON ASSOCIATES LLC added 320,008 shares (+50.0%) to their portfolio in Q2 2026, for an estimated $48,903,622
- FIRST LIGHT ASSET MANAGEMENT, LLC added 271,617 shares (+38.3%) to their portfolio in Q1 2026, for an estimated $33,857,059
- SUVRETTA CAPITAL MANAGEMENT, LLC added 261,096 shares (+29.3%) to their portfolio in Q1 2026, for an estimated $32,545,616
- PRIMECAP MANAGEMENT CO/CA/ added 195,030 shares (+inf%) to their portfolio in Q1 2026, for an estimated $24,310,489
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
